Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. Continue reading this article with a Barron’s subscription. View Options Source link
Read more Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 BillionRayzeBio Inc. RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing…
Read more RYZB Stock Price | RayzeBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatchIntraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time…
Read more RYZB Stock Price | RayzeBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
